The trial revealed a reduced risk of recurrence of BV on ending treatment with metronidazole gel when compared to placebo RR = 0.43: 0.25-0.7395% CI and 3 months post-treatment RR = 0.68: 0.49-0.9395% CI.
No es necesario realizar seguimiento de rutina a las pacientes con vaginosis bacteriana a menos que presenten recurrencia de la sintomatología o que se trate de pacientes embarazadas 4, 9.